166 related articles for article (PubMed ID: 18344628)
1. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice.
Yamashita C; Hayashi T; Mori T; Tazawa N; Kwak CJ; Nakano D; Sohmiya K; Okada Y; Kitaura Y; Matsumura Y
Hypertens Res; 2007 Dec; 30(12):1219-30. PubMed ID: 18344628
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice.
Yamashita C; Hayashi T; Mori T; Matsumoto C; Kitada K; Miyamura M; Sohmiya K; Ukimura A; Okada Y; Yoshioka T; Kitaura Y; Matsumura Y
Life Sci; 2010 Feb; 86(9-10):322-30. PubMed ID: 20060397
[TBL] [Abstract][Full Text] [Related]
3. Celiprolol reduces oxidative stress and attenuates left ventricular remodeling induced by hypoxic stress in mice.
Nishioka S; Yoshioka T; Nomura A; Kato R; Miyamura M; Okada Y; Ishizaka N; Matsumura Y; Hayashi T
Hypertens Res; 2013 Nov; 36(11):934-9. PubMed ID: 23784509
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling.
Essick EE; Ouchi N; Wilson RM; Ohashi K; Ghobrial J; Shibata R; Pimentel DR; Sam F
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H984-93. PubMed ID: 21666115
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin reduces oxidative stress and attenuates intermittent hypoxia-induced left ventricular remodeling in lean mice.
Inamoto S; Yoshioka T; Yamashita C; Miyamura M; Mori T; Ukimura A; Matsumoto C; Matsumura Y; Kitaura Y; Hayashi T
Hypertens Res; 2010 Jun; 33(6):579-86. PubMed ID: 20300107
[TBL] [Abstract][Full Text] [Related]
6. Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression.
Yu H; Zhao G; Li H; Liu X; Wang S
Gene; 2012 Apr; 497(2):301-6. PubMed ID: 22326534
[TBL] [Abstract][Full Text] [Related]
7. Inhalation of hydrogen gas attenuates left ventricular remodeling induced by intermittent hypoxia in mice.
Hayashi T; Yoshioka T; Hasegawa K; Miyamura M; Mori T; Ukimura A; Matsumura Y; Ishizaka N
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H1062-9. PubMed ID: 21642501
[TBL] [Abstract][Full Text] [Related]
8. Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress.
Hayashi T; Yamashita C; Matsumoto C; Kwak CJ; Fujii K; Hirata T; Miyamura M; Mori T; Ukimura A; Okada Y; Matsumura Y; Kitaura Y
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2197-203. PubMed ID: 18326795
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.
Tsuda M; Iwai M; Li JM; Li HS; Min LJ; Ide A; Okumura M; Suzuki J; Mogi M; Suzuki H; Horiuchi M
Hypertension; 2005 Apr; 45(4):545-51. PubMed ID: 15723967
[TBL] [Abstract][Full Text] [Related]
10. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment.
Cheng XW; Murohara T; Kuzuya M; Izawa H; Sasaki T; Obata K; Nagata K; Nishizawa T; Kobayashi M; Yamada T; Kim W; Sato K; Shi GP; Okumura K; Yokota M
Am J Pathol; 2008 Aug; 173(2):358-69. PubMed ID: 18583318
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
Nishio M; Sakata Y; Mano T; Yoshida J; Ohtani T; Takeda Y; Miwa T; Masuyama T; Yamamoto K; Hori M
J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
[TBL] [Abstract][Full Text] [Related]
12. Chronic hypoxia accelerates the progression of atherosclerosis in apolipoprotein E-knockout mice.
Nakano D; Hayashi T; Tazawa N; Yamashita C; Inamoto S; Okuda N; Mori T; Sohmiya K; Kitaura Y; Okada Y; Matsumura Y
Hypertens Res; 2005 Oct; 28(10):837-45. PubMed ID: 16471178
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.
Shimada K; Murayama T; Yokode M; Kita T; Fujita M; Kishimoto C
Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):672-8. PubMed ID: 20399087
[TBL] [Abstract][Full Text] [Related]
14. The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase-2 Up-Regulation in Renovascular Hypertension.
Cau SB; Guimaraes DA; Rizzi E; Ceron CS; Gerlach RF; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):234-41. PubMed ID: 25816715
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.
Ye Y; Gong H; Wang X; Wu J; Wang S; Yuan J; Yin P; Jiang G; Li Y; Ding Z; Zhang W; Zhou J; Ge J; Zou Y
J Cardiovasc Pharmacol; 2015 Jun; 65(6):628-39. PubMed ID: 25806688
[TBL] [Abstract][Full Text] [Related]
16. Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice.
You J; Wu J; Jiang G; Guo J; Wang S; Li L; Ge J; Zou Y
J Cardiovasc Pharmacol; 2013 Feb; 61(2):142-51. PubMed ID: 23188126
[TBL] [Abstract][Full Text] [Related]
17. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
Iwai M; Chen R; Li Z; Shiuchi T; Suzuki J; Ide A; Tsuda M; Okumura M; Min LJ; Mogi M; Horiuchi M
Circulation; 2005 Sep; 112(11):1636-43. PubMed ID: 16145000
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB activation is required for adaptive cardiac hypertrophy.
Zelarayan L; Renger A; Noack C; Zafiriou MP; Gehrke C; van der Nagel R; Dietz R; de Windt L; Bergmann MW
Cardiovasc Res; 2009 Dec; 84(3):416-24. PubMed ID: 19620128
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.
Cheng XW; Song H; Sasaki T; Hu L; Inoue A; Bando YK; Shi GP; Kuzuya M; Okumura K; Murohara T
Hypertension; 2011 May; 57(5):981-9. PubMed ID: 21464389
[TBL] [Abstract][Full Text] [Related]
20. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
